ProMetic Life Sciences (PLI) Stock Price Up 1.6%
ProMetic Life Sciences Inc. (TSE:PLI)’s share price rose 1.6% on Monday . The stock traded as high as C$1.29 and last traded at C$1.27. Approximately 776,376 shares changed hands during mid-day trading, a decline of 22% from the average daily volume of 994,542 shares. The stock had previously closed at C$1.25.
PLI has been the topic of several research analyst reports. National Bank Financial increased their price objective on shares of ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. Royal Bank Of Canada dropped their price objective on shares of ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research report on Wednesday, August 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of ProMetic Life Sciences in a research report on Monday, November 20th. Finally, TD Securities dropped their price objective on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. ProMetic Life Sciences currently has an average rating of “Buy” and an average price target of C$3.50.
In related news, Director Pierre Laurin sold 82,738 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of C$1.45, for a total transaction of C$119,970.10. Also, insider Jonathan Booth purchased 75,000 shares of the stock in a transaction that occurred on Friday, October 6th. The shares were acquired at an average cost of C$1.21 per share, for a total transaction of C$90,750.00. Over the last ninety days, insiders have purchased 86,075 shares of company stock worth $108,051.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.